Penn Medicine Provider
Dermatology
Alain H. Rook, MD
5.0
(75)
Accepting new patients
Sees patients age 18 and up
Penn Dermatology Perelman
Schedule onlineCall 215-662-2737

About me

  • Director, Photopheresis Program
  • Professor of Dermatology

Education and training

  • Medical School: University of Michigan
  • Residency: McGill University Hospitals
  • Residency: Hospital of the University of Pennsylvania
  • Fellowship: McGill University Hospitals
  • Fellowship: National Institutes of Health

What my patients think about me

Average Rating
5.0

75 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

April 2025
5.0
5.0
he is aware of my health issues and considers my whole health before deciding to actions on what is next.
April 2025
5.0
5.0
very competent.
March 2025
5.0
5.0
dr rook is the best
March 2025
5.0
5.0
dr rook is expert, thorough, kind. the perfect doctor.

Insurance accepted

My Locations

Learn about location

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: On the medical staff, but does not have privileges to treat patients in the hospital.
Dr. Rook is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Weiner DM, Clark AK, Bhansali RS, Pappas-Taffer L, Barta SK, Villasenor-Park J, Haun PL, Vittorio CC, Rook AH, Kim EJ, Samimi SS. Usage and safety of topical tacrolimus in patients with mycosis fungoides , Clin Exp Dermatol.: 2022

Nihal M, Wu J, Stonesifer CJ, Daniels J, Choi J, Geskin L, Rook AH, Wood GS. Epigenetic Regulation of Apoptosis in Cutaneous T-Cell Lymphoma: Implications for Therapy with Methotrexate, Jak Inhibitors, and Resveratrol , J Invest Dermatol. , 142(2): 2022,493-496

Lewis DJ, Rook AH. Combination therapies for mycosis fungoides/Sézary syndrome: biologic rationale and recommendations , Int J Dermatol., 60(9): 2021,e362-e364

Lewis DJ, Haun PL, Samimi SS, Vittorio CC, Villasenor-Park J, Barta SK, Landsburg DJ, Svoboda J, Nasta SD, Schuster SJ, Rook AH, Kim EJ. Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome , JAMA Dermatol. , 157(3): 2021,317-321

Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC Clinically significant responses achieved with romidespsin across disease compartments in patients with cutaneous T-cell lymphoma , Leuk Lymphoma : 2015,1-22

Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Waksman J, Whittaker S. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. , Leuk Lymphoma, 20: 2015,1-22

Cedeno-Laurent F, Singer Em, Wysocka M, Benoit BM, Vittorio CC, Kim EJ, Yosipovitch G, Rook AH. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. , Clin Immunol, 158(1): 2015,1-7

Spaccarelli N, Gharavi M, Saboury B, Cheng G, Rook AH, Alavi A. Role of (18)F-fluorodeoxyglucose positron emission tomography imaging in the management of primary cutaneous lymphomas. , Hell J Nucl Med, 17(2): 2014,78-84

Wysocka M, Kossenkov AV, Benoit BM, Troxel AB, Singer E, Schaffer A, Kim B, Dentchev T, Nagata S, Ise T, Showe LC, Rook AH. CD164 and FCRL3 are highly expressed on the CD4+CD26- T-cells in Sezary Syndrome patients. , J Invest Dermatol, 134: 2014,229-36

Samimi S, Chu E, Seykora J, Loren A, Vittorio C, Rook A, Rosenbach M, Kim EJ. Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia. , JAMA Dermatol, 149(5): 2013